From: "Jeffrey E." <[email protected]> To: george church < >, Subject: Re: $200K Date: Tue, 09 Sep 2014 13:35:56 +0000 will cal this afternoon On Tue, Sep 9, 2014 at 8:49 AM, george church < Sure ... at 857-225-6255 --geo > wrote: From: "Jeffrey E." Date: Tuesday, September 9, 2014 at 7:41 AM To: george church la Subject: Re: $200K free to speak today>? On Sat, Sep 6, 2014 at 9:11 AM, george church c wrote: The Androcyte business plan is to patent products based on genomic (and epi-genomic) variants which are unique to one or more supercentenarians (SC). Each such DNA variant can be used to design and manufacture variant-specific RNAi molecules, proteins, and CRISPR guide-RNAs. The CRISPR is used for changing DNA in human cells (stem cells, neurons, etc) to match the SC variant or reversible activation or inhibition of the SC-impacted gene. Since we (Androcyte) have (by far) the most SC resources (including genomic variants already undergoing computational analyses) and have co-invented the CRISPR technology, we are in unique position to develop these therapies swiftly. These products will be tested in animals and in partnerships with pharmaceutical and skin care companies. Pharmaceuticals are becoming more costly due to increasingly smaller (personalized) markets (e.g. Glybera at $1.6M per treatment) -- Hence the prospect of Androcyte therapies that apply to every person (with access to reasonable health care) is a opportunity for cost reduction and better margins due to huge markets. We will submit the first patent by Dec 2014 and begin CRISPR experiments and partnering discussions immediately thereafter. Examples of potential partners for Androcyte: —George From: "jeffrey E." <[email protected]> Date: Thursday, September 4, 2014 at 1:54 PM To: george church Richard Kahn Subject: Re: FW: $200K is there and was there a biz plan? how does the co intend to make money? when/ ? the use of funds , appears more like a research